MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.07
-0.19
-1.55%
Closed 16:41 05/29 EDT
OPEN
12.43
PREV CLOSE
12.26
HIGH
12.52
LOW
11.73
VOLUME
179.43K
TURNOVER
--
52 WEEK HIGH
15.82
52 WEEK LOW
4.550
MARKET CAP
302.43M
P/E (TTM)
-4.2692
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EIGR stock price target is 34.50 with a high estimate of 56.00 and a low estimate of 22.00.

EPS

EIGR News

More
Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being
PR Newswire · 2d ago
Eiger to Present at Jefferies Virtual Healthcare Conference 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Health
PR Newswire · 5d ago
FDA accepts Eiger Bio application for lonafarnib for rare aging disorder
Under Priority Review status, the FDA accepts Eiger BioPharmaceuticals' (NASDAQ:EIGR) marketing application seeking approval of Zokinvy (lonafarnib) for th
seekingalpha · 05/20 01:26
Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
PR Newswire · 05/19 21:05
Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?
Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks · 05/15 12:57
78 Biggest Movers From Yesterday
Gainers
Benzinga · 05/12 09:02
54 Stocks Moving In Monday's Mid-Day Session
Gainers
Benzinga · 05/11 16:39
Eiger BioPharmaceuticals Q1 EPS $(0.620) Up From $(0.900) YoY
Eiger BioPharmaceuticals (NASDAQ:EIGR) reported quarterly losses of $(0.620) per share. This is a 31.11 percent increase over losses of $(0.900) per share from the same period last year.
Benzinga · 05/07 20:39

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About EIGR

Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).
More

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.